Updated:
GeoVax Labs, Inc.
GeoVax Labs, Inc. (GOVX) is a publicly traded biotech developing vaccines for infectious diseases and cancers, with no disclosed investment portfolio.
GeoVax Labs, Inc.
GeoVax Inc maintains a profile on LinkedIn. The account lists 18 followers.
General information
Firm type
other
Frequently asked questions
Does GeoVax Labs operate as a family office or investment firm?
No. GeoVax Labs is a publicly traded biotechnology company (NASDAQ: GOVX) that develops vaccines and immunotherapies. It does not manage assets for families or external investors.
What is GeoVax Labs' primary business?
It is a clinical-stage biotech using its MVA viral vector platform to create vaccines for COVID-19, HIV, and cancers. Its revenue comes from grants, partnerships, and equity raises, not investment returns.
Does GeoVax Labs make direct investments or back external funds?
No. GeoVax is not an investment firm. It focuses on research and development of vaccine candidates, with no publicly disclosed investment portfolio or fund commitments.
Who leads GeoVax Labs?
As of 2025, David Dodd serves as CEO and Chairman (per SEC filings). The company's management team includes scientific and operational executives, not investment professionals.
What is the source of GeoVax Labs' funding?
GeoVax raises capital through public equity offerings, government grants (e.g., from the U.S. National Institutes of Health), and collaborative agreements. It does not manage an externally invested fund.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: